ATE242641T1 - Behandlung von stressinduzierten hautkrankheiten unter verwendung von corticoliberin (crh)- antagonisten und inhibitoren der hautmastzell- degranulation - Google Patents
Behandlung von stressinduzierten hautkrankheiten unter verwendung von corticoliberin (crh)- antagonisten und inhibitoren der hautmastzell- degranulationInfo
- Publication number
- ATE242641T1 ATE242641T1 AT97936413T AT97936413T ATE242641T1 AT E242641 T1 ATE242641 T1 AT E242641T1 AT 97936413 T AT97936413 T AT 97936413T AT 97936413 T AT97936413 T AT 97936413T AT E242641 T1 ATE242641 T1 AT E242641T1
- Authority
- AT
- Austria
- Prior art keywords
- crh
- skin
- inhibitors
- stress
- agent
- Prior art date
Links
- 102100021752 Corticoliberin Human genes 0.000 title abstract 6
- 210000003630 histaminocyte Anatomy 0.000 title abstract 6
- KLVRDXBAMSPYKH-RKYZNNDCSA-N corticotropin-releasing hormone (human) Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(N)=O)[C@@H](C)CC)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CO)[C@@H](C)CC)C(C)C)C(C)C)C1=CNC=N1 KLVRDXBAMSPYKH-RKYZNNDCSA-N 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 208000017520 skin disease Diseases 0.000 title abstract 2
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 title 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 abstract 5
- 101000895481 Homo sapiens Corticoliberin Proteins 0.000 abstract 4
- 102000050267 Neurotensin Human genes 0.000 abstract 2
- 101800001814 Neurotensin Proteins 0.000 abstract 2
- 230000004913 activation Effects 0.000 abstract 2
- PCJGZPGTCUMMOT-ISULXFBGSA-N neurotensin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 PCJGZPGTCUMMOT-ISULXFBGSA-N 0.000 abstract 2
- 206010003645 Atopy Diseases 0.000 abstract 1
- 102100027869 Moesin Human genes 0.000 abstract 1
- 102000005157 Somatostatin Human genes 0.000 abstract 1
- 108010056088 Somatostatin Proteins 0.000 abstract 1
- 230000000903 blocking effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 108010071525 moesin Proteins 0.000 abstract 1
- 230000026731 phosphorylation Effects 0.000 abstract 1
- 238000006366 phosphorylation reaction Methods 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 abstract 1
- 229960000553 somatostatin Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2228—Corticotropin releasing factor [CRF] (Urotensin)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/689,277 US6020305A (en) | 1996-08-06 | 1996-08-06 | Treatment of stress-induced skin disease by corticotropin releasing hormone antagonists and skin mast cell degranulation inhibitors |
| PCT/US1997/013776 WO1998005354A2 (en) | 1996-08-06 | 1997-08-06 | Treatment of stress-induced skin disease by corticotropin releasing hormone antagonists and skin mast cell degranulation inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE242641T1 true ATE242641T1 (de) | 2003-06-15 |
Family
ID=24767751
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97936413T ATE242641T1 (de) | 1996-08-06 | 1997-08-06 | Behandlung von stressinduzierten hautkrankheiten unter verwendung von corticoliberin (crh)- antagonisten und inhibitoren der hautmastzell- degranulation |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US6020305A (de) |
| EP (1) | EP0942749B1 (de) |
| AT (1) | ATE242641T1 (de) |
| AU (1) | AU3908997A (de) |
| DE (1) | DE69722809T2 (de) |
| ES (1) | ES2201315T3 (de) |
| WO (1) | WO1998005354A2 (de) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6984667B2 (en) * | 1998-04-08 | 2006-01-10 | Theta Biomedical Consulting And Development Co. | Synergistic proteoglycan compositions for inflammatory conditions |
| US7906153B2 (en) * | 1998-04-08 | 2011-03-15 | Theta Biomedical Consulting & Development Co., Inc. | Anti-inflammatory compositions for treating multiple sclerosis |
| US20080153761A1 (en) * | 1998-04-08 | 2008-06-26 | Theoharides Theoharis C | Compositions for protection against superficial vasodilator flush syndrome, and methods of use |
| US7799766B2 (en) * | 1998-04-08 | 2010-09-21 | Theta Biomedical Consulting & Development Co., Inc. | Composition for treating hormonally-dependent cancers |
| US20050220909A1 (en) * | 2004-03-30 | 2005-10-06 | Theoharides Theoharis C | Composition for protection against superficial vasodilator flush syndrome |
| US20040230559A1 (en) * | 1999-08-09 | 2004-11-18 | Mark Newman | Information processing device and information processing method |
| US7923043B2 (en) * | 2004-03-30 | 2011-04-12 | Theta Biomedical Consulting & Development Co., Inc. | Method for protecting humans against superficial vasodilator flush syndrome |
| US9050275B2 (en) * | 2009-08-03 | 2015-06-09 | Theta Biomedical Consulting & Development Co., Inc. | Methods of screening for and treating autism spectrum disorders and compositions for same |
| US9176146B2 (en) * | 2009-08-03 | 2015-11-03 | Theta Biomedical Consulting & Development Co., Inc. | Methods of treating autism spectrum disorders and compositions for same |
| EP3802851A4 (de) * | 2018-06-11 | 2022-03-30 | University of Florida Research Foundation, Inc. | Materialien und verfahren zur behandlung von stressbedingten störungen und krebs |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2639828B1 (fr) * | 1988-12-01 | 1993-11-05 | Lvmh Recherche | Utilisation du kaempferol et de certains de ses derives pour la preparation d'une composition cosmetique ou pharmaceutique |
-
1996
- 1996-08-06 US US08/689,277 patent/US6020305A/en not_active Expired - Lifetime
-
1997
- 1997-08-06 ES ES97936413T patent/ES2201315T3/es not_active Expired - Lifetime
- 1997-08-06 DE DE69722809T patent/DE69722809T2/de not_active Expired - Lifetime
- 1997-08-06 AT AT97936413T patent/ATE242641T1/de not_active IP Right Cessation
- 1997-08-06 EP EP97936413A patent/EP0942749B1/de not_active Expired - Lifetime
- 1997-08-06 WO PCT/US1997/013776 patent/WO1998005354A2/en active IP Right Grant
- 1997-08-06 AU AU39089/97A patent/AU3908997A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US6020305A (en) | 2000-02-01 |
| AU3908997A (en) | 1998-02-25 |
| WO1998005354A3 (en) | 1998-05-14 |
| EP0942749A2 (de) | 1999-09-22 |
| DE69722809T2 (de) | 2004-05-19 |
| DE69722809D1 (de) | 2003-07-17 |
| ES2201315T3 (es) | 2004-03-16 |
| EP0942749B1 (de) | 2003-06-11 |
| WO1998005354A2 (en) | 1998-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE293989T1 (de) | Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten | |
| ATE322283T1 (de) | Transdermale verwendung von sekretin zur behandlung von autismus | |
| DE69332713D1 (de) | Verwendung von Histamine-2 Agonisten zur Behandlung sexueller Funktionsstörungen | |
| ATE390142T1 (de) | Synergistische zusammensetzung zur behandlung von diabetes mellitus | |
| FI960727A0 (fi) | Neurokiniiniantagonisteina käyttökelpoiset heterosyklit | |
| ATE446751T1 (de) | Verwendung von methylnaltrexon zur behandlung von immunsuppression | |
| DE60326370D1 (de) | Verwendung von cgrp-antagonisten-verbindungen zur behandlung von psoriasis | |
| NO20024646D0 (no) | Kombinasjonsterapier med vaskul¶r-skadende aktivitet | |
| ATE242641T1 (de) | Behandlung von stressinduzierten hautkrankheiten unter verwendung von corticoliberin (crh)- antagonisten und inhibitoren der hautmastzell- degranulation | |
| NO971341D0 (no) | Promoter for reseptor tyrosinkinase TIE | |
| DE60140960D1 (de) | Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis | |
| PT684816E (pt) | Composicoes antagonistas do receptor da 5-ht2 uteis no tratamento de doencas venosas | |
| DE69733557D1 (de) | Endothelin-antagonisten zur behandlung von herzversagen | |
| TW200503709A (en) | Itching treating agent containing piperidine derivative as active ingredient | |
| DK0862454T3 (da) | CTLA-8 i kombination med G-CSF eller med G-CSF og IL-6 og anvendelse af CTLA-8 til behandling af infektioner | |
| DK1231908T3 (da) | Farmaceutisk præparat, der omfatter en NO-donorforbindelse samt anvendelse heraf | |
| DE69734349D1 (de) | Behandlung von knochenleiden mit adrenomedullin | |
| BR0015424A (pt) | Análogos de ácido hidroxieicosatetraenóico e, métodos de seu uso em tratamento de distúrbios de olho seco | |
| AR002258A1 (es) | Derivados de fenoxipirimidinilo, preparaciones farmaceuticas que los contienen, un procedimiento para su preparacion y su empleo para preparar medicamentos | |
| RS49796B (sr) | UPOTREBA SOLI 3α, 7α-DIHIDROKSI-12-KETO-5β-HOLANSKE KISELINE KAO AKTIVNE SUPSTANCE ZA IZRADU LEKOVA ZA LEČENJE DIJABETESA | |
| UA26886C2 (uk) | Солі 1,3-діарил-4,5-поліметилеhімідазолію, що виявляють аhальгезуючу активhість |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |